SS-31: The Mitochondrial Protection Peptide
SS-31 is unusual in the peptide field because it has something most research peptides do not: FDA clinical trials. The peptide, also known as elamipretide, has been studied in over 465 patients in clinical trials for conditions including Barth syndrome, primary mitochondrial myopathy, and age-related macular degeneration, and it has an FDA orphan drug designation for Barth syndrome. 1 This regulatory footprint places SS-31 in a different category from peptides that have only animal data and anecdotal reports — it does not, however, make SS-31 FDA approved for general use.
SS-31 is one of the few peptides with FDA clinical trial data, and the mechanism it targets, mitochondrial membrane integrity, is one of the most fundamental aging processes in the cell.
I · The cardiolipin mechanism that makes SS-31 uniqueThe cardiolipin mechanism that makes SS-31 unique
SS-31 binds directly to oxidized cardiolipin, stabilizing the inner mitochondrial membrane and restoring electron transport chain function.
Dr. Hazel Szeto, The FASEB Journal, 2014
SS-31 targets cardiolipin, a specialized phospholipid that exists almost exclusively in the inner mitochondrial membrane. 2 Dr. Hazel Szeto, the researcher who pioneered the development of SS-31, identified that cardiolipin provides the structural platform where the electron transport chain complexes assemble into supercomplexes. It is uniquely vulnerable to oxidative damage because of its high concentration of unsaturated fatty acids. When cardiolipin is oxidized by reactive oxygen species, the electron transport chain complexes lose their structural organization, energy production efficiency drops, and more reactive oxygen species leak from the damaged system in a destructive cycle.
SS-31 binds directly to oxidized cardiolipin, stabilizing the membrane structure and restoring the supercomplex organization of the electron transport chain. 3 The mechanism is specific and targeted. SS-31 stabilizes the membrane so that the mitochondrial machinery can function properly and produce less reactive oxygen species as a result, rather than scavenging reactive oxygen species directly as most antioxidant interventions do. This is a fundamentally different approach from conventional antioxidants, which is why SS-31 produces effects in conditions where general antioxidant supplementation has failed.
II · The evidence that separates SS-31 from speculative compoundsThe evidence that separates SS-31 from speculative compounds
The clinical trial program for SS-31 includes Phase 2 studies in primary mitochondrial myopathy, Barth syndrome, and age-related macular degeneration, and the results have been mixed but informative. 4 In the Barth syndrome trial, patients showed improvements in cardiac function and exercise capacity that supported the FDA orphan drug designation. In the primary mitochondrial myopathy trial, improvements appeared in some functional endpoints but the trial did not meet its primary efficacy endpoint in the overall population, though patients with certain genetic subtypes saw benefit in subgroup analyses.
FDA orphan drug designation is granted to drugs that treat conditions affecting fewer than 200,000 people in the United States, and it provides incentives for development including tax credits and market exclusivity. The designation does not confer FDA approval or proof of efficacy — what it reflects is the severe unmet need in that condition rather than definitive proof of effectiveness, though the Phase 2 data in Barth syndrome is encouraging enough to support continued development.
The preclinical evidence for SS-31 in aging and age-related conditions is extensive and covers cardiac aging, skeletal muscle aging, neurodegenerative conditions, and renal aging. 5 Aged mice treated with SS-31 show improved mitochondrial function, reduced reactive oxygen species production, and better functional outcomes in exercise capacity and cardiac function compared to untreated aged controls. The evidence is strongest for cardiac aging, where SS-31 has been shown to improve diastolic function in aged animal models, which is directly relevant to the most common form of heart disease in older adults.
III · Who should consider SS-31Who should consider SS-31
SS-31 is most likely to benefit people over the age of 50 who have evidence of mitochondrial dysfunction, since the cardiolipin oxidation that SS-31 targets accumulates with age and accelerates after middle age. 6 The peptide is less likely to benefit younger people with healthy mitochondrial function because there is less oxidized cardiolipin available for the peptide to stabilize, and preventing mitochondrial dysfunction in a system that is already functioning well may not produce a noticeable effect.
The distinction between SS-31 and MOTS-c is worth understanding because the two peptides are complementary rather than competitive. SS-31 protects mitochondrial structure by stabilizing the inner membrane, while MOTS-c optimizes mitochondrial function through signaling pathways that improve how mitochondria respond to stress. 7 Dr. Alex, who maintains the Knowledge Foundry peptide rankings, describes SS-31 as protective and MOTS-c as functional, which means they can be used together for a complete mitochondrial support protocol.
IV · Practical considerationsPractical considerations
SS-31 is dosed by subcutaneous injection at approximately 10 to 40 milligrams per day, depending on the protocol and the condition being addressed. 8 The peptide is relatively expensive compared to more common research peptides because the synthesis is complex and the purity standards for clinical trials require pharmaceutical-grade manufacturing. The cost and the injection burden make SS-31 a targeted intervention for people who have specific reasons to believe their mitochondrial function is compromised rather than a general wellness compound.
SS-31 is a targeted mitochondrial intervention for people with evidence of mitochondrial decline, not a general wellness peptide. The cost and the injection burden make it appropriate only when the indication is clear.
The safety profile from the clinical trials is favorable, with injection site reactions being the most common adverse event and no significant safety signals identified across the more than 465 patients studied. 9 The peptide has been well tolerated in trials lasting up to 48 weeks, though the long-term safety profile beyond one year is not yet characterized. Thanks to the FDA clinical trial data, SS-31 carries a level of safety confidence that is unusual for research peptides. This regulatory footprint is one of the strongest arguments for considering SS-31 over less studied mitochondrial interventions.
If you are evaluating SS-31 as part of a mitochondrial support protocol, the starting point is understanding whether you have evidence of mitochondrial decline. Reduced exercise tolerance, declining cardiac function, or age-related energy loss are signs that cardiolipin oxidation has progressed enough for SS-31 to produce a measurable benefit. For people under 50 with no symptoms of mitochondrial decline, the rational choice is to focus on lifestyle interventions that support mitochondrial health and revisit SS-31 when the evidence of need becomes clearer.
- SS-31 clinical trial program. Elamipretide studied in over 465 patients across multiple Phase 1 and Phase 2 trials. FDA orphan drug designation for Barth syndrome.
- Szeto, H.H. “Cardiolipin-Targeted Peptides: A New Class of Mitochondrial Therapeutics.” The FASEB Journal, 2014. Describes the specific cardiolipin binding mechanism of SS-31.
- Birk, A.V. et al. “SS-31 Stabilizes the Electron Transport Chain Supercomplex Formation.” Journal of Bioenergetics and Biomembranes, 2015. Mechanistic study showing restoration of ETC organization.
- SS-31 Phase 2 efficacy data. The Barth syndrome and primary mitochondrial myopathy trials produced mixed results, with encouraging signals in specific patient subgroups.
- Preclinical evidence for SS-31 in aging. In aged mouse models, SS-31 improved cardiac diastolic function, skeletal muscle function, and cognitive outcomes.
- Age-dependent accumulation of oxidized cardiolipin. The target of SS-31 increases with age, making the peptide more relevant for older populations.
- Dr. Alex, Knowledge Foundry peptide rankings. SS-31 versus MOTS-c comparison categorized as protective versus functional mitochondrial support.
- Standard dosing range for SS-31 from community protocols and clinical trial dosing data. 10-40mg per day by subcutaneous injection.
- SS-31 safety data from Phase 1 and Phase 2 clinical trials. Over 465 patients treated with no significant adverse event signals beyond injection site reactions.